Corewell Health and Michigan State University College of Human Medicine, Grand Rapids, Michigan, U.S.A.; and.
NeuroPace, Inc, Mountain View, CA, U.S.A.
J Clin Neurophysiol. 2024 Nov 1;41(7):630-639. doi: 10.1097/WNP.0000000000001060. Epub 2024 Jan 9.
PURPOSE: Owing to its extensive, reciprocal connectivity with the cortex and other subcortical structures, the thalamus is considered an important target for neuromodulation in drug-resistant focal epilepsy. Using corticothalamic stimulation, it is possible to modulate both the thalamus and the cortical seizure onset zone. Limited published clinical experience describes corticothalamic stimulation with depth leads targeting one of the anterior (ANT), centromedian (centromedian nucleus), or pulvinar (PUL) thalamic nuclei. However, it is not clear which of these nuclei is the "best" therapeutic target. METHODS: This study comprised a single-center experience with corticothalamic responsive neurostimulation using the RNS System to target these three thalamic nuclei. Presented here are the methods for target selection and device programming as well as clinical outcomes and a comparison of ictal and nonictal electrophysiological features. RESULTS: In this small retrospective study ( N = 19), responsive corticothalamic neurostimulation was an effective therapy for 79% of patients (≥50% reduction in disabling seizure frequency), regardless of whether the thalamic lead was implanted in the ANT ( N = 2), PUL ( N = 6), or centromedian nucleus ( N = 11). Twenty-six percent of patients reported a reduction in disabling seizure frequency ≥90%. Both high frequency (≥100 Hz) and low (≤20 Hz) frequency were used to stimulate the thalamus depending on the patient's response and ability to tolerate higher charge densities. In all patients, a longer burst duration (2000-5000 ms) was ultimately implemented on the thalamic leads. Across patients, peaks in the intracranial EEG were observed at theta, beta, gamma, and sleep spindle frequencies. Changes in frequency content and distribution were observed over time in all three nuclei. CONCLUSIONS: These results indicate that both high frequency and low frequency corticothalamic responsive neurostimulation can potentially be an effective adjunctive therapy in drug-resistant focal epilepsy. These data can also contribute to a broader understanding of thalamic electrophysiology in the context of focal epilepsy.
目的:由于丘脑与皮质和其他皮质下结构广泛的相互连接,因此被认为是耐药性局灶性癫痫的神经调节的重要靶点。使用皮质丘脑刺激,可以调节丘脑和皮质癫痫起始区。有限的已发表的临床经验描述了使用靶向前丘脑(ANT)、中央中核(centromedian nucleus)或丘脑枕(pulvinar)核之一的皮质丘脑刺激的深度导联。然而,目前尚不清楚这些核中的哪一个是“最佳”治疗靶点。
方法:本研究为使用 RNS 系统针对这三个丘脑核进行皮质丘脑反应性神经刺激的单中心经验。本文介绍了目标选择和设备编程的方法以及临床结果,并比较了发作期和非发作期的电生理特征。
结果:在这项小型回顾性研究(N=19)中,反应性皮质丘脑神经刺激是 79%的患者(致痫性发作频率降低≥50%)的有效治疗方法,无论丘脑导联植入 ANT(N=2)、丘脑枕(N=6)还是中央中核(N=11)。26%的患者报告致痫性发作频率降低≥90%。根据患者的反应和对更高电荷密度的耐受能力,高频(≥100 Hz)和低频(≤20 Hz)均可用于刺激丘脑。在所有患者中,最终在丘脑导联上实施了更长的爆发持续时间(2000-5000 ms)。在所有患者中,颅内 EEG 均观察到θ、β、γ和睡眠纺锤波频率的峰值。随着时间的推移,在所有三个核中均观察到频率含量和分布的变化。
结论:这些结果表明,高频和低频皮质丘脑反应性神经刺激都可能是耐药性局灶性癫痫的有效辅助治疗方法。这些数据还可以为局灶性癫痫背景下的丘脑电生理学提供更广泛的理解。
J Clin Neurophysiol. 2024-11-1
Cochrane Database Syst Rev. 2017-7-18
Cochrane Database Syst Rev. 2014-6-17
Cochrane Database Syst Rev. 2012-9-12
Biol Psychiatry Cogn Neurosci Neuroimaging. 2024-8-23
medRxiv. 2024-3-8